Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Adults with Migraine
From Neurology Minute · 02:18
Show by American Academy of Neurology
Dr. Tesha Monteith discusses growing evidence supporting CGRP-targeted therapies as first-line preventive treatment options for people with migraine. Show citation: Reuter U, Dycke AV, Versijpt J, et al. Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial. Lancet Neurol. 2026;25(9):806-817. doi:10.1016/S1474-4422(26)00214-0
More episodes of Neurology Minute
More episodes
- October 26, 2026 Capitol Hill Report: Conrad 30
- Facial Pain Series - Part 1
- Youth Football and the Epidemic of Pediatric Brain Injury - Part 2
- Youth Football and the Epidemic of Pediatric Brain Injury - Part 1
- Acute Optic Neuropathy in Older Adults
- Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis
- Trends in Emergent Interfacility Ischemic Stroke Transfers
- Clinical Reasoning: Rapidly Progressive Cranial Neuropathies, Weakness, and Ataxia in a Patient With MS
- Optimizing Management of Episodic Cluster Headache
- Rethinking Seronegative NMOSD
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.